Objective To explore the effect of microRNA-374b-5p on proliferative diabetic retinopathy. Methods Based on retrospective study, the peripheral blood of patients with diabetic non-proliferative (NPDR, n=30) and proliferative (PDR, n=32) retinopathy was collected, and the contents of microRNA-374b-5p and VEGF were determined, correlation analysis was performed at the same time, miR-374b-5p was introduced into endothelial cells to detect the expression of VEGF and the changes of endothelial cells' angiogenesis ability. Results Compared with NPDR group (7.993±6.194), the expression of serum miR-374b-5p in PDR group (4.308±3.313) decreased significantly (P<0.05). Compared with the content of VEGF in NPDR group [ (35.50±21.49)pg/ml], the content of VEGF in PDR group [((74.64±26.57)pg /ml] was significantly higher, and the difference was statistically significant (P<0.05). There was a negative correlation between miR-374b-5p and VEGF (R2=0.088, P=0.019). The level of miR-374b-5p in serum of PDR patients decreased and VEGF increased, which was negatively correlated with each other, while miR-374b-5p could inhibit the expression of VEGF mRNA and protein, and inhibit the angiogenesis ability of endothelial cells. Conclusions The decline of miR-374b-5 in the progress of PDR leads to a decline in its ability to resist the increase of VEGF expression, and induces an increase in endothelial cell angiogenesis, thereby promoting the occurrence and development of PDR.
Key words
diabetic proliferative retinopathy /
microRNA /
vascular endothelial growth factor /
endothelial cells /
angiogenesis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9): 948-959.
[2] Song P, Yu J, Chan K Y, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis [J]. J Glob Health, 2018, 8(1):10803.
[3] 王 鸿, 李晓静, 刘 佳, 等. 2型糖尿病患者血浆氧化三甲胺与视网膜病变的相关性 [J]. 武警医学, 2022, 33(8): 654-658.
[4] 张换想, 邱洪斌, 张艺潆. 糖尿病视网膜病变的危险因素[J]. 牡丹江医学院学报, 2022, 43(3): 64-68.
[5] Gong Q, Xie J, Liu Y, et al. Differentially expressed microRNAs in the development of early diabetic retinopathy [J]. J Diabetes Res, 2017, 2017: 4727942.
[6] Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization [J]. Diabetes Res Clin Pract, 1999, 44(1): 21-26.
[7] Chobanian A V, Bakris G L, Black H R, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure [J]. Hypertension, 2003, 42(6): 1206-1252.
[8] 李 瑞, 李万明, 陈小丽. 微小RNA-126和血管内皮生长因子在增殖性糖尿病视网膜病变患者视网膜前膜中的表达及意义 [J]. 实用临床医药杂志, 2022, 26(2): 1-5,10.
[9] 王 涛, 崔月玲, 王晓聪, 等. 糖尿病性视网膜病变患者血清microRNA-20a-5p、VEGF水平变化及其临床意义 [J]. 中国现代医学杂志, 2021, 31(21): 20-25.
[10] 李继红, 牛梦琦. 血管内皮生长因子水平对2型糖尿病患者并发视网膜微血管病变的预测价值 [J]. 实用医学杂志, 2022, 38(8): 1001-1005.
[11] Li E H, Huang Q Z, Li G C, et al. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene [J]. Biosci Rep, 2017, 37(2):45-56.
[12] Mcarthur K, Feng B, Wu Y, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy [J]. Diabetes, 2011, 60(4): 1314-1323.
[13] Bartel D P. MicroRNAs: target recognition and regulatory functions [J]. Cell, 2009, 136(2): 215-233.
[14] Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications [J]. J Cardiovasc Transl Res, 2012, 5(4): 413-422.
[15] Singer M A, Kermany D S, Waters J, et al. Diabetic macular edema: it is more than just VEGF [J]. F1000 Res, 2016, 1:5.
PDF(1064 KB)
